06.01.2021 • News

UK Regulator Investigates Tronox TiZir Buy

The UK’s Competition and Markets Authority (CMA) intends to open a Phase 2 investigation into Tronox’s proposed purchase of the TiZir titanium and iron business from French multinational mining and metallurgy group Eramet.

However, Tronox said that as a standard part of the process, the company may offer remedies to the CMA before it reaches a final decision on whether to begin the investigation. 

Under the terms of the takeover announced in May 2020, Tronox agreed to pay approximately $300 million for the TiZir business, which upgrades ilmenite to high-grade titanium slag and high-purity pig iron. The facility in Tyssedal, Norway, has annual capacities of 230,000 t/y of titanium slag and 90,000 t/y pig iron. The US pigment producer said the “highly strategic” acquisition would lower the cost of obtaining feedstock for its titanium operations.

While the proposed takeover did not require notification in the UK, or meet premerger reporting thresholds in the US, regulators in both countries launched investigations. A decision from the US Federal Trade Commission is still awaited.

Author: Elaine Burridge, Freelance Journalist

The UK’s Competition and Markets Authority is to open a Phase 2 investigation...
The UK’s Competition and Markets Authority is to open a Phase 2 investigation into Tronox’s proposed purchase of the TiZir titanium and iron business from French mining and metallurgy group Eramet. However, Tronox may offer remedies to the CMA before it reaches a final decision. (c) Tronox

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read